Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

Translated title of the contribution: AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab

Research output: Contribution to journalArticle

Abstract

The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42% at 3 years and with an overall survival rate of 35% at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.

Translated title of the contributionAACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab
Original languageItalian
Pages (from-to)414-7
Number of pages4
JournalRecenti Progressi in Medicina
Volume107
Issue number8
DOIs
Publication statusPublished - Aug 2016

Keywords

  • English Abstract
  • Journal Article

Fingerprint Dive into the research topics of 'AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab'. Together they form a unique fingerprint.

  • Cite this